Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (493 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-01-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 14.4% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 820 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 35.9% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Minimum age: 2 (lowers risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: visitscreeningironextensionanemia
  Phrases that lowered it: participantsulnevaluatecreatininepatients
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 94.2% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 224 (raises risk) · Sponsor's track record
• Maximum age: 17 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Keywords listed: 12 (raises risk) · Design
• Disease area, metabolic: Yes (lowers risk) · Disease area
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) NCT02125877 · started 2014 · scored riskier than 41% of active trials completed
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation NCT02720536 · started 2016 · scored riskier than 41% of active trials completed
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study NCT00873041 · started 2008 · scored riskier than 52% of active trials completed
• Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet NCT02993224 · started 2017 · scored riskier than 63% of active trials completed
• Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients NCT01825512 · started 2014 · scored riskier than 33% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.